Myriad Genetics, Inc. (MYGN): Upgrade News

MYGN – Morgan Stanley raises to overweight. Stock price at the time of this analyst call was $38.03.

Update: As of Mar. 22, 2019, this bullish analyst call has returned -12.96%.

Key Facts Surrounding This News Item

  • MYGN had a POWR Rating of B (Buy) coming into today.
  • MYGN was 1.16% above its 10-Day Moving Average coming into today.
  • MYGN was -0.83% below its 20-Day Moving Average coming into today.
  • MYGN was 5.05% above its 50-Day Moving Average coming into today.
  • MYGN was 14.25% above its 100-Day Moving Average coming into today.
  • MYGN was 12.04% above its 200-Day Moving Average coming into today.
  • MYGN had returned +10.73% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.

More Info About Myriad Genetics, Inc. (MYGN)

Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah. View our full MYGN ticker page with ratings, news, and more.

MYGN at a Glance

MYGN Current POWR Rating™
Overall POWR Rating™
MYGN Current Price $33.10 1.25%
More MYGN Ratings, Data, and News

MYGN Price Reaction

The day of this event (Jul. 11, 2018)
MYGN Closing Price$43.04 13.17%
MYGN Volume3,920,700
378.66% from avg
Leading up to this event
MYGN 1-mo return2.69%
After this event
MYGN 1-day return11.48%
MYGN 3-day return9.50%
MYGN 5-day return11.19%

MYGN Price Chart

More Myriad Genetics, Inc. (MYGN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MYGN News
Page generated in 0.8145 seconds.